Literature DB >> 1655118

Mechanisms of resistance to drugs that inhibit DNA topoisomerases.

W T Beck1, M K Danks.   

Abstract

DNA topoisomerases are essential nuclear enzymes that are involved in DNA replication. Clinically useful antitumor drugs such as doxorubicin, daunorubicin (anthracyclines), etoposide, teniposide (epipodophyllotoxins), and amsacrine (an aminoacridine) interfere with the function of topoisomerase II and camptothecin and its analogs inhibit topoisomerase I. Some mammalian tumor cells that express resistance to drugs that interfere with topoisomerase I or topoisomerase II have alterations in their respective topoisomerases. In this paper, we review the functions of the topoisomerases, discuss aspects of their cellular regulation, ask how interference with topoisomerase function can lead to tumor cell death, discuss the biochemical features of tumor cells that are resistant to these anti-topoisomerase drugs, and, in the context of drug resistance, we raise questions about how these drugs exert their cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655118

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  19 in total

1.  Modulation of gyrase-mediated DNA cleavage and cell killing by ATP.

Authors:  T K Li; L F Liu
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis.

Authors:  M Stanulla; J Wang; D S Chervinsky; S Thandla; P D Aplan
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 3.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Altered DNA topoisomerase II in multidrug resistance.

Authors:  W T Beck; M K Danks; J S Wolverton; B Granzen; M Chen; C A Schmidt; B Y Bugg; E Friche; D P Suttle
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 5.  Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.

Authors:  W T Beck; R Kim; M Chen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

Review 7.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 8.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 9.  Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.

Authors:  M Pomeroy; M Moriarty
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.